Frequently Asked Questions
The global cancer biological therapy market was valued at USD 111945.8 Million in 2022.
The cancer biological therapy market is expected to grow at a CAGR of 7.5% between 2023 and 2030, reaching USD 199652.8 Million in 2030.
Monoclonal antibodies (mAbs) are the leading segment by therapeutic approach, holding over 30% share in value in 2022.
The breast cancer segment governs the global demand for cancer biological therapy, holding a massive market share of over 25% in 2022.
The cancer clinics segment will post the highest CAGR over the projection period.
North America is propelling the rapid expansion of the cancer biological therapy industry, accounting for more than one-third of its market share in 2022.
The top players include F. Hoffmann-La Roche Ltd, Mylan N.V., Teva Pharmaceutical Industries Ltd, Sanofi, Pfizer Inc, GSK Plc, Novartis AG, Bayer AG, Merck & Co. Inc, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma, Lupin, Endo Pharmaceuticals Plc, Zydus Group, Bausch Health Companies Inc, and Others.
The primary market drivers of the cancer biological therapy industry include developments in immunotherapy and precision medicine, rising cases of cancer, and expanding applicability across multiple cancer types.
The major market restraints of the cancer biological therapy industry encompass high treatment costs and regulatory challenges, hindering accessibility and adoption.
The major market opportunities in the cancer biological therapy industry involve expanding applications to various cancer types and exploring combination therapies, along with addressing the unmet medical needs of pediatric patients and emerging markets in regions like the Asia Pacific.